Novel AI Tool Helps Patients to Find, Understand Clinical Trials

Article

Cancertrialsearch.com helped to match patients with gastrointestinal cancers to clinical trials using 7 different criteria, possibly paving the way for patients to find, understand, and enroll in oncology clinical trials.

According to an ongoing study presented at the 2020 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium, a novel artificial intelligence (AI)-based search tool is now making it easier for patients to find and understand oncology clinical trials, while simultaneously offering more clarity on how patients can enroll in them.

Cancertrialsearch.com helped to match patients with gastrointestinal (GI) cancers to clinical trials using 7 different criteria, including trial sponsor, trial phase, tumor type, cancer stage, across solid tumors, by genetic mutations, and by previous treatment.

“Patients have limited access to an understanding of clinical trials and the online search tools that we have available – not only for patients, but even for providers – can be very hard to navigate,” study author Pashtoon Kasi, MD, MS, clinical assistant professor of internal medicine, hematology, oncology and blood and marrow transplantation at the University of Iowa Health Care, said during a virtual presentation at the symposium.

Improving understanding and access to clinical trials may result in more representative trial enrollment. Lack of diversity in clinical trials has been an issue that many researchers are facing, and can result in, “sometimes devastating medical consequences,” the researchers wrote.

After utilizing cancertrialsearch.com, participants were asked to complete a 20-minute survey evaluating both clinicaltrials.gov – which is commonly used for searching for trials – and the novel tool cancertrialsearch.com. Patients used a 5-point Likert scale to rate aspects of usability for each platform.

“We took GI clinical trials as an example of how this would be applicable to several other tumor types,” Kasi said. “The trial information is restructured based on key eligibility differentiators, [and] is patient-focused in terms of providing questionnaires that have been based on eligibility differentiators, which could be further personalized, and a value for institutions as well as patient advocacy groups.”

At baseline, the average rating for participants’ understanding of clinical trials was 3.1 (±1.2). Patient associations and the internet were their main sources of information about trials. Finding clinical trials was easier for patients using cancertrialsearch.com, compared to not using the tool (3.7±0.9 vs. 2.7±1.3, respectively).

Additionally, the researchers said that the tool improved patients’ understanding of information presented (3.8±1.1 vs. 2.6±1.3); and directionally provided more clarity on how to enroll in trials (4.2±0.8 vs. 3.7±1.4). Ultimately, these factors led to improved patient satisfaction (3.4±1.1 vs. 2.3±0.5).

Cancertrialsearch.com also could lead to better connection among principal investigators, patients and caregivers, and advocacy groups.

“In summary, with this cancertrialsearch.com tool, personalizing and simplifying client information can lead to better patient comprehension, as well as ease of access and navigation, leading to better patient satisfaction and an increased trial pool,” Kasi said. “This could mean broader and more diverse patient pool.”

Reference:

Kasi PM, Jordan E, Jahreiss L. Deploying an AI-based online search tool to increase patients’ access to and understanding of solid tumor GI clinical trials. J Clin Oncol. 2021;39 (suppl 3). Abstract #: 456.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content